Microbix mobilizes SWATT team to help companies worldwide expand flu vaccine production
Microbix Biosystems Inc. is establishing a Special Workgroup for Applied technology transfer (SWATT) that shall be instrumental in helping manufacturers significantly boost the amount of flu vaccine produced throughout the world.
The SWATT team will be sent to facilities adopting the Microbix proprietary virus yield enhancement technology - VIRUSMAX(TM). The team is expected to be operational this Fall. It will spend several weeks in each location helping customers implement the technology and training local personnel.
At present, only about 350 million doses of flu vaccine are produced annually in the world. There are only three countries that produce enough vaccine domestically to immunize their populations - Canada, France, and Australia. Every other country lacks the manufacturing capacity to meet its own needs. The largest domestic deficits are the U.S., China and India.
According to the company, Microbix' technology has been proven to double vaccine production output. It was also announced that Australia has indicated that it will issue a patent on this technology to Microbix. Similar patent protection has already been allowed in the U.S., Canada and India, and a number of other applications in major markets are currently pending.
Other news from the department research and development
